Loading
A phase 2 trial of Patritumab deruxtecan in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT04619004 by Daiichi Sankyo, with 277 participants enrolled, started 2021-02-02 and due to reach its primary completion in 2022-11-21. Interventions recorded: Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration). Conditions listed: Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor. Results were posted on ClinicalTrials.gov in 2024; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
277 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2024-04-02), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)primary | Patritumab Deruxtecan 5.6 mg/kg | 225 | 64 participants | - | - | link |
| Patritumab Deruxtecan Up-Titration | 50 | 8 participants |
Shares Patritumab deruxtecan, Daiichi Sankyo, EGFR-mutated non-small-cell lung cancer, Antibody-drug conjugate (ADC).
Shares Patritumab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
Shares Patritumab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Patritumab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Patritumab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Patritumab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Daiichi Sankyo, Antibody-drug conjugate (ADC), Small-cell lung cancer, Non-small-cell lung cancer.